Bioresearch Monitoring Program:Concerns
Changes in the clinical trial landscape
- More studies; more CIs and sites per study
- Expansion and fluidity of CI pool
- Delegation of functions/authority
- New players in new roles (CROs, SMOs)
- New technologies (electronic record-keeping)
- Trials in geographic areas new to FDA expectations and requirements